Literature DB >> 2333285

Interleukin 6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammapathy.

Y Levy1, J P Fermand, S Navarro, C Schmitt, W Vainchenker, M Seligmann, J C Brouet.   

Abstract

Blood B cells from eight patients with clonal lymphoid disorders characterized by monoclonal IgM secretion (four with malignant plasmacytic proliferation typical of Waldenström macroglobulinemia and four without overt lymphoid neoplasia) were found to spontaneously differentiate in vitro into plasma cells. In all instances, monoclonal plasma cells (8-45% of the cells) were generated from extensively purified B cells or T-cell-depleted peripheral blood mononuclear cells after a 7-day culture period, with a corresponding high rate of IgM secretion into the culture medium. This differentiation occurred in the absence of any cell proliferation process as measured by [3H]thymidine uptake at day 2 or 4. Normal B cells did not differentiate under the same experimental conditions. Detection of interleukin 6 (IL-6) bioactivity in all patients' B-cell culture supernatants as well as of IL-6 mRNA in freshly prepared, uncultured B cells in the two cases studied by in situ hybridization suggested that IL-6 secretion by B cells may play a role in this process. Moreover, in the four patients without overt lymphoid proliferation, B-cell differentiation was significantly inhibited (60-80%) in the presence of anti-IL-6 antibodies. In contrast, anti-IL-6 antibodies did not preclude the differentiation into plasma cells of B cells from the four patients with bona fide Waldenström macroglobulinemia. These results suggest a two-step pathogenesis for such human lymphoplasmacytic clonal proliferations, the initial stage being characterized by an IL-6-dependent autocrine differentiation pathway.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2333285      PMCID: PMC53889          DOI: 10.1073/pnas.87.9.3309

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Peripheral neuropathy associated with monoclonal IgM autoantibody.

Authors:  A J Steck; N Murray; K Dellagi; J C Brouet; M Seligmann
Journal:  Ann Neurol       Date:  1987-12       Impact factor: 10.422

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 3.  Molecular regulation of B lymphocyte response.

Authors:  T Kishimoto; T Hirano
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

4.  Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies.

Authors:  T Matsuda; T Hirano; T Kishimoto
Journal:  Eur J Immunol       Date:  1988-06       Impact factor: 5.532

5.  Synergistic activation of human T cells by interleukin 1 and interleukin 6.

Authors:  F A Houssiau; P G Coulie; D Olive; J Van Snick
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

6.  Production of hybridoma growth factor by human monocytes.

Authors:  L A Aarden; E R De Groot; O L Schaap; P M Lansdorp
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

7.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

Authors:  K Ikebuchi; G G Wong; S C Clark; J N Ihle; Y Hirai; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

9.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.

Authors:  A Muraguchi; T Hirano; B Tang; T Matsuda; Y Horii; K Nakajima; T Kishimoto
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.

Authors:  M Lotz; F Jirik; P Kabouridis; C Tsoukas; T Hirano; T Kishimoto; D A Carson
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  8 in total

1.  A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.

Authors:  X Mariette; C Chastang; P Clavelou; J P Louboutin; J M Leger; J C Brouet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

3.  Endotoxin induced production of interleukin-6 is enhanced by vitamin E deficiency and reduced by black tea extract.

Authors:  A M Amarakoon; P S Tappia; R F Grimble
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

4.  Interleukin-7 is a growth factor for Sézary lymphoma cells.

Authors:  A Dalloul; L Laroche; M Bagot; M D Mossalayi; C Fourcade; D J Thacker; D E Hogge; H Merle-Béral; P Debré; C Schmitt
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

5.  Ectopic lymphokine gene expression in human peripheral blood lymphocytes in vivo.

Authors:  C A Chambers; J Kang; N Hozumi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

6.  Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas.

Authors:  S M Hsu; S S Xie; J A Waldron
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

Review 7.  Interleukin-6, a new target for therapy in multiple myeloma?

Authors:  M H van Oers; H C van Zaanen; H M Lokhorst
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

Review 8.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.